Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficiency of the Lidcombe Program for early stuttering by varying the time between clinic visits during the first stage of the program.


Clinical Trial Description

Stuttering is a communicative disorder that affects an estimated 5.19% of children. Although approximately 71.4% of children whose stuttering onset is in the preschool years exhibit spontaneous recovery within two years after first reported onset, there remain a significant number of children who require fluency intervention. Given the potential for negative long term social and communicative consequences due to persistent stuttering, there is a consensus among speech-language pathologists that stuttering should be treated early. However, the longer a child's stuttering persists, the less likely the child will spontaneously recover.

The Lidcombe Program is a behavioral therapy program for preschool children designed to treat stuttering at its early stages. The treatment approach involves the direct participation of parents, who are trained during parent and child weekly visits to a speech language pathologist. In the first stage of the program, the clinician demonstrates the therapy to the parent, observes the parent conduct therapy and provides feedback and goals for the following week until the next clinic visit. The clinician guides the parent to provide three types of verbal "reinforcement" contingencies for the child's stutter free speech. These include, acknowledgment, praise and request for self-evaluation, where the child is asked to recognize his or her stutter free speech. If unambiguous stuttering occurs, the parent provides two types of verbal "punishment" contingencies including acknowledgment of the stuttering and request for self-correction, where the child is asked to repeat the stuttered word again. These contingencies are administered by parents in everyday speaking conversations, in order to promote generalization of fluent speech. When the child's stuttering is reduced to near-zero levels, the child then enters the second stage of the program, where the number of clinic visits are gradually phased out from bi-monthly to monthly to every 2 months, and so on, as required by the child. The purpose of the stage 2 visits is for the speech language pathologist to evaluate the child's speech and to ensure that near-zero stuttering levels are maintained.

When the first stage of the Lidcombe program is followed as the program was originally designed, the median treatment time to achieve the criteria of near-zero levels of stuttering is 11 one-hour weekly clinic visits, with treatment times varying according to the severity of the stuttering. However, clinicians have been deviating from the standard weekly sessions for various reasons. For instance, some private practitioners are offering first stage treatment visits once every 2 weeks rather than weekly and other practitioners are offering treatment intensively, so that clients from remote areas can have access to the Lidcombe program. As yet, there are no data to confirm whether treatment using fortnightly or twice weekly clinic visits is as effective or efficient as the standard weekly visits. The aim of this project is to evaluate the following questions: (1) Does altering the spacing of LP clinic visits affect treatment efficiency? (2) Does altering the spacing of LP clinic visits affect treatment efficacy? ;


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research


Related Conditions & MeSH terms


NCT number NCT00680303
Study type Interventional
Source University of Sydney
Contact Mark Onslow
Email M.Onslow@usyd.edu.au
Status Recruiting
Phase Phase 2
Start date January 2008
Completion date December 2010

See also
  Status Clinical Trial Phase
Suspended NCT01684657 - A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering Phase 3
Not yet recruiting NCT05437627 - Computerized Based Analysis for Detection and Severity Assessment of Stuttering
Completed NCT02288598 - Enhancing Speech Fluency With Non-invasive Brain Stimulation in Developmental Stuttering N/A
Completed NCT00001602 - Genetic Factors Related to Stuttering N/A
Active, not recruiting NCT04082104 - Assessment of Stuttering Severity in Adults and Adolescences in Conversational and Narrative Contexts
Completed NCT04580966 - IBSR Intervention for Adults Who Stutter N/A
Recruiting NCT00148161 - Activity of the Auditory Cortex During Speech Perception and Speech Production in Stuttering N/A
Recruiting NCT05908123 - Exploring the Nature, Assessment and Treatment of Stuttering N/A
Completed NCT00001551 - Characteristics of Idiopathic Familial Speech Disorders N/A
Withdrawn NCT01315730 - The Effects of Tactile Speech Feedback on Stuttering Frequency Phase 1
Completed NCT00004991 - Study of Brain Activity During Speech Production and Speech Perception N/A
Recruiting NCT05286151 - Network Connectivity and Temporal Processing in Adolescents Who Stutter N/A
Completed NCT00001604 - Genetic Linkage Studies of Stuttering
Recruiting NCT00709072 - Follow-up of Children After Stuttering Treatment Phase 2
Completed NCT00830154 - A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering Phase 2/Phase 3
Completed NCT03698539 - How Stuttering and Gestures Influence the Intelligibility of Individuals With Down Syndrome
Completed NCT04505696 - Providing Speech Therapy Awareness in Private Schools N/A
Recruiting NCT04929184 - Speech Processing in Stuttering N/A
Terminated NCT00001308 - Central Mechanisms in Speech Motor Control Studied With H215O PET
Completed NCT01097161 - Stuttering and Apraxia of Speech: the Efficacy of an Intervention Program N/A